News

Gilotrif was initially approved in the US in July 2013 to treat epidermal growth factor receptor (EGFR)-positive metastatic non-small cell lung cancer (NSCLC). It has now been approved

Under the agreement, TGI would be Quark’s preferred provider of gene expression profiling services related to their clinical trial. The primary objective of the Quark/TGI collaboration will be

In this study, ZEPATIER demonstrated superiority on efficacy and safety endpoints compared to sofosbuvir plus pegIFN/RBV, based on pre-specified analyses. In the full analysis set (FAS) (n=255), the

ExxPharma will be responsible for technical development while Halo will have overall responsibility of drug product manufacturing and quality control at Halo’s state-of-the art GMP-compliant manufacturing facility in

The agreement provides Takeda access to Presage’s proprietary CIVO technology platform to enable identification of novel oncology drug combinations in solid tumors. Under the agreement, Presage and Takeda

The MoU confirms PICI and PsiOxus’s interest in working together to develop and test novel "armed" oncolytic viral constructs utilizing PsiOxus’ proprietary T-SIGn platform and manufacturing capabilities. Under

Lundbeckfond Ventures, Bay City Capital and Alexandria Venture Investments have also participatd in the round. Imara will develop IMR-687, a disease-modifying therapeutic selected specifically to treat sickle cell

Under the exclusive channel collaboration (ECC), AmpliPhi received an exclusive worldwide license to use Intrexon’s technology for the standardized production of wild type phages and for the design

The agency will review the submission under priority review status which reduces the review time to six months from the standard 10 months. In May 2014, the FDA